{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(4)"],"submitter":["Hayashi S"],"pubmed_abstract":["<h4>Background</h4>In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for BRCA1/2 mutation carriers who developed breast or ovarian cancer. The amount of BRCA1/2 genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients' outcomes remain unclear.<h4>Patients and methods</h4>This study explored the potential number of patients who will be eligible for new insurance coverage for BRCA1/2 genetic testing. We "],"journal":["Breast cancer (Tokyo, Japan)"],"pagination":["659-665"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9225975"],"repository":["biostudies-literature"],"pubmed_title":["Genetic medicine is accelerating in Japan."],"pmcid":["PMC9225975"],"pubmed_authors":["Nakamura M","Morisaki T","Takao Y","Hayashi S","Kaneshiro K","Shimazaki A","Yamada M","Kubo M","Kai M","Shikada S"],"additional_accession":[]},"is_claimable":false,"name":"Genetic medicine is accelerating in Japan.","description":"<h4>Background</h4>In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for BRCA1/2 mutation carriers who developed breast or ovarian cancer. The amount of BRCA1/2 genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients' outcomes remain unclear.<h4>Patients and methods</h4>This study explored the potential number of patients who will be eligible for new insurance coverage for BRCA1/2 genetic testing. We ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-05-29T19:01:57.841Z","creation":"2024-10-19T08:37:14.59Z"},"accession":"S-EPMC9225975","cross_references":{"pubmed":["35191009"],"doi":["10.1007/s12282-022-01342-4"]}}